Literature DB >> 19853955

Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.

Nobuhiko Hiraga1, Michio Imamura, Tsuyoshi Hatakeyama, Shosuke Kitamura, Fukiko Mitsui, Shinji Tanaka, Masataka Tsuge, Shoichi Takahashi, Hiromi Abe, Toshiro Maekawa, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Takaji Wakita, Kazuaki Chayama.   

Abstract

BACKGROUND/AIMS: Both hepatitis B virus (HBV) and hepatitis C virus (HCV) replicate in the liver and show resistance against innate immunity and interferon (IFN) treatment. Whether there is interference between these two viruses is still controversial. We investigated the interference between these two viruses and the mode of resistance against IFN.
METHODS: We performed infection experiments with either or both of the two hepatitis viruses in human hepatocyte chimeric mice. Huh7 cell lines with stable production of HBV were also established and transfected with HCV JFH1 clone. Mice and cell lines were treated with IFN. The viral levels in mice sera and culture supernatants and messenger RNA levels of IFN-stimulated genes were measured.
RESULTS: No apparent interference between the two viruses was seen in vivo. Only a small (0.3 log) reduction in serum HBV and a rapid reduction in HCV were observed after IFN treatment, regardless of infection with the other virus. In in vitro studies, no interference between the two viruses was observed. The effect of IFN on each virus was not affected by the presence of the other virus. IFN-induced reductions of viruses in culture supernatants were similar to those in in vivo study.
CONCLUSIONS: No interference between the two hepatitis viruses exists in the liver in the absence of hepatitis. The mechanisms of IFN resistance of the two viruses target different areas of the IFN system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853955     DOI: 10.1016/j.jhep.2009.09.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

1.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

2.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

Authors:  Laura Belloni; Lena Allweiss; Francesca Guerrieri; Natalia Pediconi; Tassilo Volz; Teresa Pollicino; Joerg Petersen; Giovanni Raimondo; Maura Dandri; Massimo Levrero
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

3.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

4.  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.

Authors:  Xiaoming Cheng; Yuchen Xia; Elisavet Serti; Peter Daniel Block; Michelle Chung; Kazuaki Chayama; Barbara Rehermann; T Jake Liang
Journal:  Hepatology       Date:  2017-12       Impact factor: 17.425

5.  Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity.

Authors:  Jianhua Li; Kuancheng Liu; Yang Liu; Yan Xu; Fei Zhang; Huijuan Yang; Jiangxia Liu; Tingting Pan; Jieliang Chen; Min Wu; Xiaohui Zhou; Zhenghong Yuan
Journal:  Nat Immunol       Date:  2013-07-07       Impact factor: 25.606

6.  Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus.

Authors:  Chunxiao Xu; Haitao Guo; Xiao-Ben Pan; Richeng Mao; Wenquan Yu; Xiaodong Xu; Lai Wei; Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype.

Authors:  Yuchen Xia; Xiaoming Cheng; Yao Li; Kristin Valdez; Weiping Chen; T Jake Liang
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

Review 8.  Experimental models and therapeutic approaches for HBV.

Authors:  Maura Dandri; Marc Lütgehetmann; Jörg Petersen
Journal:  Semin Immunopathol       Date:  2012-08-17       Impact factor: 9.623

9.  TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.

Authors:  Audrey Boyer; Seung Bum Park; Ynto S de Boer; Qisheng Li; T Jake Liang
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

10.  Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.

Authors:  Wenbo Zhu; Chunchen Wu; Wanyu Deng; Rongjun Pei; Yun Wang; Liang Cao; Bo Qin; Mengji Lu; Xinwen Chen
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.